Difficulty: Medium
Average Score: 87%
Practice
What is the goal of pharmacologic therapy in the treatment of ParkinsonÔÇÖs disease?
Correct answer
C
Rationale
In the treatment of Parkinson's disease, the goal of pharmacologic therapy is to balance cholinergic and dopaminergic activity in the brain, which is why option C is correct. Dopamine is a neurotransmitter that is deficient in Parkinson's disease, leading to motor symptoms. By aiming to balance cholinergic (acetylcholine) and dopaminergic activity, medications can help alleviate symptoms and improve motor function in patients with Parkinson's disease.
Option A, to increase the amount of acetylcholine at the pre-synaptic neurons, is incorrect because Parkinson's disease is primarily characterized by a lack of dopamine, not acetylcholine. Option B, to reduce the amount of dopamine available in the substantia nigra, is also incorrect as the goal is to increase dopamine levels to compensate for the deficiency. Option D, to block dopamine receptors in pre-synaptic and post-synaptic neurons, is not aligned with the treatment approach for Parkinson's disease, which focuses on enhancing dopamine activity rather than blocking it.
Educationally, understanding the goals of pharmacologic therapy in Parkinson's disease is crucial for pediatric nurses caring for patients with this condition. By grasping the rationale behind the medications used, nurses can ensure safe administration, monitor for effectiveness, and educate patients and families on the purpose and expected outcomes of treatment. This knowledge enhances the quality of care provided to pediatric patients with Parkinson's disease and contributes to better patient outcomes.
Option A, to increase the amount of acetylcholine at the pre-synaptic neurons, is incorrect because Parkinson's disease is primarily characterized by a lack of dopamine, not acetylcholine. Option B, to reduce the amount of dopamine available in the substantia nigra, is also incorrect as the goal is to increase dopamine levels to compensate for the deficiency. Option D, to block dopamine receptors in pre-synaptic and post-synaptic neurons, is not aligned with the treatment approach for Parkinson's disease, which focuses on enhancing dopamine activity rather than blocking it.
Educationally, understanding the goals of pharmacologic therapy in Parkinson's disease is crucial for pediatric nurses caring for patients with this condition. By grasping the rationale behind the medications used, nurses can ensure safe administration, monitor for effectiveness, and educate patients and families on the purpose and expected outcomes of treatment. This knowledge enhances the quality of care provided to pediatric patients with Parkinson's disease and contributes to better patient outcomes.